OBJECTIVE: To assess whether there was a difference in HIV seroprevalence between eligible women who declined and those who agreed to participate in a study of voluntary counseling and testing among women entering labor with unknown HIV status in South Africa. METHODS: Anonymous cord blood specimens were collected-as dried blood spots-from all women approached for participation in a cluster-randomized trial. No patient identifiers were included on the cord blood specimens. The dried blood spots were analyzed for HIV antibody via enzyme immunoassay and western blotting. RESULTS: Of 7238 women screened for study participation, 1041 (14.4%) had undocumented HIV status; of these women, 542 were eligible for inclusion and 343 enrolled. Based on 513 evaluable samples, the overall seroprevalence was 13.3% (95% confidence interval [CI], 10.4-16.5), which was similar to the 13.1% (95% CI, 9.7-17.2) seroprevalence among the 343 enrolled women. CONCLUSION: Seroprevalence among eligible women was similar to that among enrolled women, which indicates that study participation did not select for a group with an HIV seroprevalence substantially different from that among women who declined to enroll.
OBJECTIVE: To assess whether there was a difference in HIV seroprevalence between eligible women who declined and those who agreed to participate in a study of voluntary counseling and testing among women entering labor with unknown HIV status in South Africa. METHODS: Anonymous cord blood specimens were collected-as dried blood spots-from all women approached for participation in a cluster-randomized trial. No patient identifiers were included on the cord blood specimens. The dried blood spots were analyzed for HIV antibody via enzyme immunoassay and western blotting. RESULTS: Of 7238 women screened for study participation, 1041 (14.4%) had undocumented HIV status; of these women, 542 were eligible for inclusion and 343 enrolled. Based on 513 evaluable samples, the overall seroprevalence was 13.3% (95% confidence interval [CI], 10.4-16.5), which was similar to the 13.1% (95% CI, 9.7-17.2) seroprevalence among the 343 enrolled women. CONCLUSION: Seroprevalence among eligible women was similar to that among enrolled women, which indicates that study participation did not select for a group with an HIV seroprevalence substantially different from that among women who declined to enroll.
Authors: Kathryn Stinson; Andrew Boulle; Peter J Smith; Elizabeth M Stringer; Jeffrey S A Stringer; David Coetzee Journal: J Acquir Immune Defic Syndr Date: 2012-06-01 Impact factor: 3.731
Authors: Gerhard B Theron; David E Shapiro; Russell Van Dyke; Mae P Cababasay; Jeanne Louw; D Heather Watts; Elizabeth Smith; Marc Bulterys; Robert Maupin Journal: Int J Gynaecol Obstet Date: 2011-01-19 Impact factor: 3.561
Authors: Harriet Mpairwe; Lawrence Muhangi; Proscovia B Namujju; Andrew Kisitu; Alex Tumusiime; Moses Muwanga; James A G Whitworth; Saul Onyango; Benon Biryahwaho; Alison M Elliott Journal: J Acquir Immune Defic Syndr Date: 2005-07-01 Impact factor: 3.731
Authors: Taha E Taha; Newton I Kumwenda; Donald R Hoover; Susan A Fiscus; George Kafulafula; Chiwawa Nkhoma; Samah Nour; Shu Chen; George Liomba; Paolo G Miotti; Robin L Broadhead Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: Marc Bulterys; Denise J Jamieson; Mary Jo O'Sullivan; Mardge H Cohen; Robert Maupin; Steven Nesheim; Mayris P Webber; Russell Van Dyke; Jeffrey Wiener; Bernard M Branson Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: Dmitry M Kissin; Natalia Akatova; Aza G Rakhmanova; Elena N Vinogradova; Evgeny E Voronin; Denise J Jamieson; M Kathleen Glynn; Alexey Yakovlev; Joanna Robinson; William C Miller; Susan Hillis Journal: Am J Obstet Gynecol Date: 2008-02 Impact factor: 8.661